Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Manufacturing (cGMP) deviations

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards.

1,754 FDA drug recalls with this cause, newest first.

This category covers departures from current Good Manufacturing Practice during production. It is FDA's broadest label, used when a facility's own process control failed somewhere along the line even if no single ingredient was proven unsafe on its own. Where the report names a specific consequence - a temperature excursion, a contaminant, a potency problem - we file the recall under that more specific cause instead; what remains here is the genuinely general case.

Class II · Moderate risk

Zyprexa Intramuscular

cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

Terminated cGMP deviation Eli Lilly & Company NDC 0002-7597-01 D-0720-2021
Class II · Moderate risk

Oxygen

cGMP deviations

Terminated cGMP deviation Grace Healthcare Medical, Inc D-0355-2021
Class II · Moderate risk

China-Gel White

CGMP deviations: Product being recalled as it was made in the same facility where contamination with B. cepacia was found in other products.

Ongoing cGMP deviation China Gel Inc NDC 76305-301-02 D-0789-2021
Class II · Moderate risk

CHINA_GEL (Camphor 3.00%, Menthol 5.00%)

CGMP deviations: Product being recalled as it was made in the same facility where contamination with B. cepacia was found in other products.

Ongoing cGMP deviation China Gel Inc NDC 76305-300-13 D-0788-2021